BeyondSpring is a clinical stage biopharma focused on immuno-oncology cancer therapies. It developed Plinabulin for chemotherapy-induced neutropenia and non-small cell lung cancer. CEO and co-founder Dr. Lan Huang, a structural biologist by training, joined us to discuss Q4 milestones, the potential for Plinabulin, industry trends, 2022 outlook and why small molecule therapy is never going to go away.